Protara TherapeuticsTARA
TARA
About: Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Employees: 27
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
433% more call options, than puts
Call options by funds: $16K | Put options by funds: $3K
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
0.11% less ownership
Funds ownership: 50.75% [Q2] → 50.64% (-0.11%) [Q3]
8% less funds holding
Funds holding: 38 [Q2] → 35 (-3) [Q3]
14% less capital invested
Capital invested by funds: $22.2M [Q2] → $19.1M (-$3.12M) [Q3]
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
271%
upside
Avg. target
$22
299%
upside
High target
$23
327%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Michael Schmidt 26% 1-year accuracy 5 / 19 met price target | 271%upside $20 | Buy Reiterated | 6 Dec 2024 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target | 327%upside $23 | Buy Reiterated | 6 Dec 2024 |
Financial journalist opinion
Based on 9 articles about TARA published over the past 30 days
Positive
Seeking Alpha
1 week ago
Protara Therapeutics: Rising From The Ashes
Protara Therapeutics' TARA-002 showed promising Phase 2 results, significantly improving its valuation and offering a strong risk-reward setup despite recent stock fluctuations. The company raised $100M at $6.25 per share, ensuring a solid cash runway for potential Phase 3 trials and further development. Protara's current enterprise value is $70.2M, significantly undervalued compared to competitors like CG Oncology and Engene Holdings, indicating substantial upside potential.
Neutral
GlobeNewsWire
1 week ago
Protara Announces Closing of $100 Million Public Offering
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,690,000 shares of its common stock at a public offering price of $6.25 per share and pre-funded warrants to purchase 2,325,372 shares of common stock at a price of $6.249 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 2,402,305 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering were approximately $100 million before deducting underwriting discounts and commissions and offering expenses payable by Protara and excluding any exercise of the underwriters' option to purchase additional shares and the exercise of any pre-funded warrants. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.
Positive
Seeking Alpha
1 week ago
Protara Therapeutics: Carving New Roads In Bladder Cancer
Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Financially, TARA has 7-8 quarters of funds, potentially extending to 3-4 years with a $100 million capital raise. Despite positive early data, the small patient sample size necessitates caution; larger trials are needed to confirm efficacy and safety.
Positive
Seeking Alpha
1 week ago
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is expected to reach $5.4 billion by 2034. Initial results from the phase 2 STARBORN-1 study, using TARA-002 for the treatment of pediatric patients with macroystic and mixed cystic LMs, are expected in the 1st half of 2025.
Neutral
GlobeNewsWire
1 week ago
Protara Announces Pricing of $100 Million Public Offering
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,690,000 shares of its common stock at a price to the public of $6.25 per share and pre-funded warrants to purchase 2,325,372 shares of common stock at a price of $6.249 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 2,402,305 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares and pre-funded warrants in the offering are being sold by Protara. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and offering expenses payable by Protara and excluding any exercise of the underwriters' option to purchase additional shares and the exercise of any pre-funded warrants. The offering is expected to close on December 11, 2024, subject to satisfaction of customary closing conditions. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.
Neutral
GlobeNewsWire
1 week ago
Protara Announces Proposed Public Offering
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be offered by Protara. In addition, Protara expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.
Neutral
Benzinga
2 weeks ago
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
Positive
Zacks Investment Research
2 weeks ago
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
Positive
Benzinga
2 weeks ago
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?
On Thursday, Protara Therapeutics Inc. TARA stock traded higher after the company revealed results from its ongoing Phase 2 open-label ADVANCED-2 trial.
Neutral
GlobeNewsWire
1 month ago
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 25th Annual Meeting of the Society of Urologic Oncology (SUO) taking place December 4, 2024 to December 6, 2024, in Dallas, Texas. The presentation will include safety data featured in the abstract published today on the SUO website, as well as updated safety and new efficacy data from approximately 20 enrolled patients, the majority of whom are six-month evaluable.
Charts implemented using Lightweight Charts™